カテゴリ： GlobalData, アメリカ, 企業調査

Editas Medicine Inc (EDIT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Editas Medicine Inc (EDIT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9994
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：70
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery stage biotechnology company that develops genome level treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of genetic and infectious diseases of eye, hematologic diseases, cancer, and diseases of muscle, lung and liver. The company works in collaboration with various biotechnology and pharmaceutical companies and research institutions. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.

Editas Medicine Inc (EDIT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Editas Medicine Raises USD120 Million in Series B Financing 13
Editas Medicine Raises US$43 Million In Series A Financing 16
Partnerships 18
Editas Medicine Enters into Licensing and Option Agreement with Beam Therapeutics 18
Allergan and Editas Medicine Exercise of Options to Co-Develop EDIT-101 19
Adverum Biotechnologies Extends Agreement with Editas Medicine 20
Editas Medicine Enters into Agreement with Fondazione Telethon and Ospedale San Raffaele 21
Editas Medicine Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 22
Juno Therapeutics Enters into Research Agreement with Editas Medicine 23
Licensing Agreements 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 26
Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 28
Editas Medicine Enters into Licensing Agreement with Duke University 29
Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 30
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 31
Equity Offering 33
Editas Medicine Plans to Raise Funds through Public Offering of Securities 33
Editas Medicine Plans to Raise up to USD150 Million in Public Offering of Shares 34
Editas Medicine Raises USD57.5 Million in Public Offering of Shares 35
Editas Medicine Raises USD103.5 Million in Public Offering of Shares 37
Editas Medicine Raises USD108.6 Million in IPO 39
Editas Medicine Inc – Key Competitors 41
Editas Medicine Inc – Key Employees 42
Editas Medicine Inc – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Financial Announcements 44
Nov 07, 2018: Editas Medicine announces third quarter 2018 results and update 44
Aug 06, 2018: Editas Medicine announces second quarter 2018 results and update 46
May 03, 2018: Editas Medicine Announces First Quarter 2018 Results and Update 48
Mar 06, 2018: Editas Medicine Announces Fourth Quarter and Full Year 2017 Results and Update 50
Nov 07, 2017: Editas Medicine Announces Third Quarter 2017 Results and Update 52
Aug 09, 2017: Editas Medicine Announces Second Quarter 2017 Results and Update 54
May 15, 2017: Editas Medicine Announces First Quarter 2017 Results and Update 56
Mar 07, 2017: Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update 58
Corporate Communications 60
Oct 01, 2018: Editas Medicine Grows Scientific Leadership with two new appointments 60
Mar 28, 2018: Editas Medicine Appoints James C. Mullen As Board Chairman 61
Feb 16, 2018: Editas Medicine Appoints Jessica Hopfield, Ph.D., As Board Director 62
May 31, 2017: Editas Medicine Names Andrew Hirsch to Board of Directors 63
Mar 03, 2017: Editas Medicine Announces Departure of Chief Operating Officer 64
Government and Public Interest 65
Aug 09, 2017: Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment 65
Product News 66
12/11/2017: Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia 66
May 13, 2017: Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas 67
Clinical Trials 68
May 11, 2017: Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia 68
Other Significant Developments 69
Jan 08, 2018: Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70

List of Tables
Editas Medicine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Editas Medicine Raises USD120 Million in Series B Financing 13
Editas Medicine Raises US$43 Million In Series A Financing 16
Editas Medicine Enters into Licensing and Option Agreement with Beam Therapeutics 18
Allergan and Editas Medicine Exercise of Options to Co-Develop EDIT-101 19
Adverum Biotechnologies Extends Agreement with Editas Medicine 20
Editas Medicine Enters into Agreement with Fondazione Telethon and Ospedale San Raffaele 21
Editas Medicine Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 22
Juno Therapeutics Enters into Research Agreement with Editas Medicine 23
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 24
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 26
Editas Medicine Enters into Second Licensing Agreement with Massachusetts General Hospital 28
Editas Medicine Enters into Licensing Agreement with Duke University 29
Editas Medicine Enters into Licensing Agreement with Massachusetts General Hospital 30
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 31
Editas Medicine Plans to Raise Funds through Public Offering of Securities 33
Editas Medicine Plans to Raise up to USD150 Million in Public Offering of Shares 34
Editas Medicine Raises USD57.5 Million in Public Offering of Shares 35
Editas Medicine Raises USD103.5 Million in Public Offering of Shares 37
Editas Medicine Raises USD108.6 Million in IPO 39
Editas Medicine Inc, Key Competitors 41
Editas Medicine Inc, Key Employees 42
Editas Medicine Inc, Subsidiaries 43

List of Figures
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Editas Medicine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Editas Medicine Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Editas Medicine Inc (EDIT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Masimo Corp (MASI)：企業の財務・戦略的SWOT分析
    Masimo Corp (MASI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Deep Well Oil & Gas Inc：石油・ガス：M&Aディール及び事業提携情報
    Summary Deep Well Oil & Gas Inc (Deep Well Oil & Gas) is an oil and gas exploration and development company that acquires, explores and develops oil sands. The company operates HCSS Thermal Recovery Project and SAGD Thermal Recovery Project. Its SAGD Thermal Recovery Project operates Sawn Lake oil s …
  • Vale Canada Ltd：企業の戦略・SWOT・財務情報
    Vale Canada Ltd - Strategy, SWOT and Corporate Finance Report Summary Vale Canada Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Cascades Inc：戦略・SWOT・企業財務分析
    Cascades Inc - Strategy, SWOT and Corporate Finance Report Summary Cascades Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sunshine Biopharma Inc (SBFM)：企業の財務・戦略的SWOT分析
    Summary Sunshine BioPharma Inc (Sunshine BioPharma), a subsidiary of Advanomics Corp is a pharmaceutical company that offers research, development and commercialization of drugs for treating cancer disease. The company provides generic and proprietary drugs for the treatment of cancer and other acut …
  • Leonardo DRS Inc：企業の戦略的SWOT分析
    Leonardo DRS Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Yuhan Corp (000100)：製薬・医療：M&Aディール及び事業提携情報
    Summary Yuhan Corp (Yuhan) researches, develops, manufactures and markets pharmaceutical products. The company offers API's and intermediates for antibiotic, antiviral, antifungal, anti-inflammatory, anti-diabetic, anti-HIV, anti-HCV, beta-lactase inhibitors, PEGlyated compounds and anti-histamines. …
  • Immune Pharmaceuticals Inc (IMNP)：製薬・医療：M&Aディール及び事業提携情報
    Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a drug development company that develops novel therapies for immunologic and inflammatory diseases. The company’s pipeline products include Bertilimumab and Nanocyclo. Its Bertilimumab is a human monoclonal antibody designe …
  • Lonmin Plc：企業の戦略・SWOT・財務情報
    Lonmin Plc - Strategy, SWOT and Corporate Finance Report Summary Lonmin Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • NCR Corporation：戦略・SWOT・企業財務分析
    NCR Corporation - Strategy, SWOT and Corporate Finance Report Summary NCR Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Ego Pharmaceuticals Pty Ltd：企業の戦略的SWOT分析
    Ego Pharmaceuticals Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Redcape Hotel Group：企業の戦略・SWOT・財務分析
    Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report Summary Redcape Hotel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Bank Of Cyprus Public Company Ltd
    Bank Of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank Of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • OMV New Zealand Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary OMV New Zealand Ltd (OMV NZ) a subsidiary of OMV AG, is an oil and natural gas exploration and production company. It offers upstream production services with offshore oil and gas fields in Maari, Pohokura, and Maui across Taranaki coast, Tunisia and in the Black Sea. The company operates ex …
  • CEFC China Energy Co Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary CEFC China Energy Co Ltd (CEFC China Energy) operates as energy and financial services provider. It is engaged in offering upstream oil and gas equities and interests. The company provides financial support with licenses. It is also engaged in investments and international banking businesses …
  • Daily Mail & General Trust plc (DMGT)：企業の財務・戦略的SWOT分析
    Daily Mail & General Trust plc (DMGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Krispy Kreme Doughnuts, Inc.：企業の戦略的SWOT分析
    Krispy Kreme Doughnuts, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野：企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Luzerner Kantonalbank AG：企業の戦略・SWOT・財務分析
    Luzerner Kantonalbank AG - Strategy, SWOT and Corporate Finance Report Summary Luzerner Kantonalbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Itochu Chemical Frontier Corp：製薬・医療：M&Aディール及び事業提携情報
    Summary Itochu Chemical Frontier Corp (ICF), formerly Ando Kaseihin KK, a subsidiary of Itochu Corporation, is a chemical company that manufactures and markets chemical products. The company’s business division includes intermediate chemical division, performance product division, eco chemical and l …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆